| Literature DB >> 27026430 |
S J Whiting1, W M Kohrt2, M P Warren3, M I Kraenzlin4, J-P Bonjour5.
Abstract
Food fortification can deliver essential micronutrients to large population segments without modifications in consumption pattern, suggesting that fortified foods may be formulated for populations at risk for fragility fractures. This scoping review determined the extent to which randomized controlled studies have been carried out to test the impact of fortified foods on bone outcomes, searching PubMed for all studies using the terms 'fortified AND bone', and 'fortification AND bone'. Studies were restricted to English language, published between 1996 and June 2015. From 360 articles, 24 studies met the following criteria: human study in adults ⩾18 years (excluding pregnancy or lactation); original study of a fortified food over time, with specific bone outcomes measured pre- and post intervention. Six studies involved adults <50 years; 18 involved adults ⩾50 years. Singly or in combination, 17 studies included calcium and 16 included vitamin D. There were 1 or 2 studies involving either vitamin K, magnesium, iron, zinc, B-vitamins, inulin or isoflavones. For adults <50 years, the four studies involving calcium or vitamin D showed a beneficial effect on bone remodeling. For adults ⩾50 years, n=14 provided calcium and/or vitamin D, and there was a significant bone turnover reduction. No consistent effects were reported in studies in which addition of vitamin K, folic acid or isoflavone was assessed. Results from this scoping review indicate that up to now most studies of fortification with bone health have evaluated calcium and/or vitamin D and that these nutrients show beneficial effects on bone remodeling.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27026430 PMCID: PMC5056988 DOI: 10.1038/ejcn.2016.42
Source DB: PubMed Journal: Eur J Clin Nutr ISSN: 0954-3007 Impact factor: 4.016
EFSA positive opinions on vitamins and minerals other than calcium and vitamin D for making a bone health claim for the general population
| Vitamin K[ | Vitamin K contributes to the maintenance of normal bone | Bone structure, bone integrity, bone calcification and bone health | At least source of=11.25 μg minimum |
| Magnesium[ | Magnesium contributes to the maintenance of normal bone and teeth | Bone and teeth structure | At least source of=56.25 mg minimum |
| Phosphorus[ | Phosphorus contributes to the maintenance of normal bone and teeth | Bone and teeth structure | Not inadequate intake of Phosphorus in the general EU population |
| Manganese[ | Manganese contributes to the maintenance of normal bone | Bone formation | Not inadequate intake of Manganese in the general EU population |
| Zinc[ | Zinc contributes to the maintenance of normal bone | Bone formation | Not inadequate intake of Zinc in the general EU population |
Abbreviations: EFSA, European Food Safety Authority; EU, European Union. Table content drawn from references 26 to 30.
Table content drawn from references 26, 27, 28, 29, 30.
No justification to fortify foods with these nutrients according to EFSA.
Scoping review of food fortification trials (2000–2015) having bone health outcomes involving young adults (<50 years) or predominantly younger adults (mean age <50 years)
| Blanco-Rojo | Fruit juice | Iron | Iron-deficient women (mean 25 years) | 16 weeks | AKPase NTX | Not significant | Fe status improved |
| Dahl | Thickened fruit beverages | Inulin | Institutionalized young adults age (23–57 years) | 3 weeks | NTX | Not significant | |
| Ferrar | Ice cream | Calcium | Women (20–39 years) | 4 weeks | sCTX uNTX/Cr PTH P1NP | ↑ P1NP ↓ CTX | |
| Kruger | Milk | Calcium±vitamin K | Women (20–35 years) | 16 weeks | CTX P1NP OC | ↓ P1NP ↓ CTX | No additive effect of vitamin K to calcium |
| Tapola | Mineral water | Folic, B6, B12, vitamin D, calcium | Men and women (mean 48 years) | 8 weeks | AKPase | ↑ AKPase as measure of calcium bioavailability | |
| Toxqui | Milk | Iron±vitamin D | Iron deficiency women (18-35 y) | 16 weeks | PTH P1NP NTX | ↓ P1NP ↓ NTX (+Fe +D vs Fe alone) | Effect of iron on bone seen with correlation analysis |
Abbreviations: AKPase, alkaline phosphatase; CAN, Canada; CTX, C-terminal telopeptide (s, serum); ESP, Spain; FIN, Finland; GBR, United Kingdom; NTX, N-terminal telopeptide (u, urine); NZL, New Zealand; OC, osteocalcin; PTH, parathyroid hormone; P1NP, Procollagen Type 1 N-Terminal Propeptide.
Scoping review of food fortification trials (2000–2015) having bone health outcomes involving older adults (⩾50 years or postmenopausal women
| Adolphi | Fermented milk | Calcium, inulin, casein phospho-peptides | PM women | 2 weeks | ALP DPY | Not significant | Milk reduced night-time bone turnover |
| Bonjour | Soft cheese | Calcium, vitamin D | Nursing home PM women | 6 weeks | TRAP5b, CTX OC, PTH P1NP IGF-1 | ↓TRAP5b ↓ CTX ↓ PTH ↑ IGF-1 | |
| Bonjour | Soft cheese | Calcium, vitamin D | PM women | 6 weeks | TRAP5b, CTX OC, PTH P1NP, IGF-1 | ↓TRAP5b ↑ IGF-1 | |
| Bonjour | Yogurt | Calcium, vitamin D | Nursing home PM women | 8 weeks | TRAP5b, CTX OC, PTH P1NP, IGF-1 | ↓TRAP5b ↓ PTH | |
| Bonjour | Yogurt | Calcium, vitamin D | PM women | 12 weeks | TRAP5b, CTX OC, PTH P1NP, IGF-1 | ↓TRAP5b ↓ PTH | |
| Brink | Biscuits and bars | Isoflavones | Early PM women | 1 year | BMD PYD, DPD P1NP PTH, ALP | Not significant | |
| Daly | Milk | Calcium, vitamin D | Nursing home men | 2 years | BMD (DXA, QCT) | ↑ femoral neck BMD ↑ bone strength if >62-year-old | BMD effect is sustained after 18 months follow-up |
| Grieger | Milk | Calcium, folate, vitamin D | Nursing home women | 6 months | CTX P1NP PTH | Not significant | No additive effect of vitamin K to calcium |
| Jafari | Yogurt | Vitamin D | Type 2 Diabetic PM women | 12 weeks | NTX PTH | ↓ NTX | Dose of vitamin D was 2000 IU |
| Kanellakis | Dairy | Calcium, vitamin D,±vitamin K (K1 or K2) in 3 groups (compared to no dairy) | PM women | 1 year | BMD IGF-1 DYP, PTH | ↑ lumbar BMD with vitamin K | ↑ total body BMD with any dairy |
| Kukuljan | Milk | Calcium, vitamin D | Older men | 18 months | BMD | Not significant | Men were vitamin D replete at start |
| Green | Milk (tested against apple drink) | Magnesium | PM women | 4 weeks | CTX PTH | ↓ CTX | |
| Gui | Soy or cow milk (compared to no milk) | Calcium | PM women | 18 months | BMD | ↑ femoral neck BMD | |
| Kruger | Milk (compared to fruit drink) | Calcium, vitamin D, magnesium, zinc | PM women | 4 months | CTX, P1NP OC, PTH | ↓ CTX,↓P1NP ↓ OC.↓PTH | |
| Manios | Dairy (compared to no milk) | Calcium, vitamin D | PM women | 1 year, then 1.5 years of increased vitamin D | BMD CTX PTH IGF-1 | ↑ total body BMD (2.5 years) ↓ PTH ↑ IGF-1 | Also compared dairy to supplemental calcium and vitamin D |
| Palacios | Milk | Calcium, vitamin D – compared two doses of calcium | PM women | 10 weeks | ALP P1NP PYR NTX | Higher Ca dose ↓PYR | |
| Bonjour | Soft cheese | Calcium, vitamin D | Nursing home PM women | 4 weeks | TRAP5b, CTX OC, PTH P1NP IGF-1 | ↓TRAP5b ↓ CTX ↓ PTH ↑ IGF-1 | Compared pre- and post-treatment |
| Mocanu | Bread | Vitamin D | Nursing home | 1 year | BMD | ↑ BMD | Compared pre- and post-treatment |
Abbreviations: ALP, alkaline phosphatase; AUS, Australia; BMD, bone mineral density; CAN, Canada; CHN; China; CTX, C-terminal telopeptide (s, serum); DEU, Germany; DPY, deoxypyridinoline crosslinks; ESP, Spain; FIN, Finland; FRA, France; GBR, United Kingdom; GRC, Greece; IGF-1, insulin-like growth factor-1; IRN, Iran; ITA, Italy; NTX, N-terminal telopeptide (u, urine); NZL, New Zealand; OC, osteocalcin; PM, postmenopausal; PTH, parathyroid hormone; P1NP, Procollagen Type 1N-Terminal Propeptide; PYD, pyridinoline crosslinks; ROM, Romania; TRAP5b, Tartrate-resistant acid phosphatase (TRAP) 5b.
Multicenter PHYTOS study.
Five reports from ‘The Postmenopausal Health Study'.
Figure 1Nutrients added to foods and tested for bone effects: results of a scoping review from 1996 to 2015. Number of included studies distributed according to the added nutrients. Out of 360 articles, 24 studies, 6 and 18 in adults less than and ⩾50 years, respectively, met the predetermined following criteria: human study in adults ⩾18 years; original trial testing fortified foods over time, with specific bone outcomes measured pre- and post intervention.
Figure 2Changes (Δ) after 56 days (D56–D0) of consumption of non-fortified control or fortified yogurts in two independent double-blind randomized clinical trials. One trial (RCT-1) was carried out in women living in French (FR) nursing homes, the other (RCT-2) in women living in a Great Britain (GRB) community dwelling home. Columns represent the difference after 56 d in serum 25OHD (upper panel), PTH (middle panel) and TRAP5b (lower panel). Data are taken from two original studies published in 2013[47] and 2015.[48] In both trials, the differences in changes between fortified and control (non-fortified) yogurt groups were statistically significant for 25OHD, PTH and TRAP5b: **P<0.001; *P<0.0025.